What changed for Pancreatic Cancer
A plain English summary of what recently moved in the public data Voxsanity tracks for Pancreatic Cancer. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting worldwide 529 to 544 (+15)
- Late-stage (Phase 3) trials 45 to 46 (+1)
- Trials on record 2,789 to 2,869 (+80)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Pancreatic Cancer yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 127 trials tracked for Pancreatic Cancer that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT06528093 · results posted 15 July 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06528093) enrolled a total of eight people across three treatment groups: two participants received a lower dose of the experimental drug BI 765883 on its own (0.4 mg/kg), three received a higher dose on its own (1.3 mg/kg), and three received the lower dose combined with chemotherapy. None of the participants completed the study — all eight left before it finished. The trial was primarily looking at whether certain side effects, called dose-limiting toxicities (serious unwanted effects severe enough to affect dosing decis...
-
NCT04492800 · results posted 26 May 2026
According to the results reported on ClinicalTrials.gov, this trial looked at the use of the Paxman Scalp Cooling Device, which is a cap worn during chemotherapy treatment that cools the scalp with the aim of reducing hair loss. Nine people took part in the study, and all nine completed it. The trial was measuring three things: how much hair participants kept during chemotherapy, how comfortable participants found the cooling device, and how distressed participants felt about chemotherapy-related hair loss. The reported data shows that, when it came to hair preservation, 2 out of 9 participan...
-
NCT01585805 · results posted 19 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT01585805) enrolled 83 people in total across several groups. The trial was studying veliparib — a drug being investigated for cancer — both on its own and combined with two chemotherapy medicines (gemcitabine and cisplatin) in patients with a specific type of cancer. The trial had two main parts: a smaller, non-randomised section to find the right dose of veliparib when given alongside chemotherapy, and a randomised section where participants were assigned to one of three groups — veliparib plus chemotherapy (Arm A, 27 peo...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06119217 · results posted 13 May 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT06119217) enrolled 194 people across three groups. Sixty-six participants received TTX-030 combined with two chemotherapy drugs (nab-paclitaxel and gemcitabine); 60 received TTX-030 plus an additional drug called budigalimab alongside the same chemotherapy; and 68 received the chemotherapy drugs alone (the comparison group). The trial was primarily measuring how long participants went without their cancer getting worse — called "progression-free survival" — in a subset of participants selected based on certain biological m...
-
NCT03767582 · results posted 11 May 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 22 participants in total across five groups. Two groups took part in a Phase I safety-focused stage (3 people at a lower dose and 6 at a higher dose), and three groups took part in a Phase II stage comparing different combinations of immunotherapy drugs — nivolumab, BMS-813160, and GVAX — given alongside radiation and sometimes surgery for pancreatic cancer. The trial was measuring two main things: how many participants experienced side effects linked to the study drugs, and how many showed a notable increase (more th...
-
NCT03049189 · results posted 6 April 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT03049189) enrolled 203 people in the 177Lu-edotreotide PRRT group, 99 people in the everolimus group, and 14 people in a smaller sub-study group. The trial was mainly measuring how long people lived without their tumour growing or spreading — known as "progression-free survival" — comparing two different treatments for a type of tumour. A second thing the trial measured was the "objective response rate," which is simply the proportion of participants whose tumour shrank or disappeared during treatment. The reported data s...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02047474 · results posted 6 March 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 46 people, all of whom received a chemotherapy regimen called mFOLFIRINOX. The trial was looking at treatment for a type of cancer, and it followed participants through several stages: pre-surgery chemotherapy, surgery, and post-surgery chemotherapy. Of the 46 who started, 37 completed the pre-surgery treatment, 27 went on to have surgery, 22 began post-surgery chemotherapy, and 19 completed the full treatment journey. The trial's main goal was to measure how many participants went a certain period without their cance...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04387071 · results posted 17 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04387071) enrolled just 2 participants, both of whom completed the study. The trial was testing a combination of two investigational drugs — CMP-001 and INCAGN01949 — in people with solid tumours. The main things being measured were the proportion of participants whose cancer showed signs of shrinking or disappearing (called the "disease control rate" and "objective response rate"), assessed using standardised tumour-measuring guidelines from MRI scans. The reported data shows that neither of the 2 participants had their...
-
NCT03377491 · results posted 21 January 2026
According to the results reported on ClinicalTrials.gov, this trial enrolled 571 adults with a form of pancreatic cancer that could not be surgically removed (locally advanced). Participants were split into two groups: 285 people received a device called TTFields — which delivers low-intensity electrical fields to the body — alongside standard chemotherapy drugs (gemcitabine and nab-paclitaxel), while 286 people received chemotherapy alone. The trial's main goal was to measure how long people in each group lived overall, and secondary goals included how long before the cancer grew or spread, a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04844970 · results posted 17 November 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04844970) was studying whether a drug called anamorelin (taken at 100 mg per day) could affect body weight and appetite-related symptoms in people with pancreatic cancer that could not be cured, who were also receiving first-line chemotherapy. Participants were randomly assigned to receive either anamorelin or a placebo (a dummy treatment with no active ingredient). A total of four people took part — two in the anamorelin group and two in the placebo group. This is a very small number, which suggests the trial did not recr...
-
NCT02780648 · results posted 3 November 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 36 people across two groups: 3 in Cohort A and 33 in Cohort B. The trial was looking at the effects of a specialised type of radiation treatment called stereotactic body radiation therapy (SBRT) on people with a pancreatic condition. The main thing being measured was how many participants experienced serious (grade 3 or higher) side effects affecting the gut or blood during treatment. Secondary measurements included longer-term gut side effects, survival over time, and self-reported pain scores. The reported data sho...
-
NCT05361668 · results posted 31 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05361668) looked at a medicine called paltusotine and enrolled 36 people in total — 18 in a group starting on a 40 mg daily dose and 18 in a group starting on an 80 mg daily dose. Participants were allowed to have their dose adjusted up or down during the trial to help manage their symptoms. Of the 36 who started, 30 completed the study (17 from the 40 mg group and 13 from the 80 mg group). The main thing the trial was set up to measure was safety — specifically, how many people experienced unwanted health events (called "...
-
NCT05169437 · results posted 29 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 22 people with locally advanced or metastatic solid tumour cancers that carried a specific gene mutation called PALB2. The study was testing a drug called niraparib to see how many participants' tumours shrank or disappeared (called the "overall response rate"), how long any such response lasted, and how long participants went without their cancer getting worse (called "progression-free survival"). Of the 22 who started, 16 completed the study and 6 did not. The reported data shows that when an independent central re...
-
NCT03184870 · results posted 9 October 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03184870) enrolled a total of 376 participants across 18 different treatment groups. The trial was studying a drug called BMS-813160 given at different doses, either alone or combined with other cancer medicines, in people with colorectal cancer or pancreatic cancer. The trial was run in two parts — Part 1 focused on finding a suitable dose, and Part 2 tested selected doses further. Because the trial had so many groups with different drug combinations and dose levels, the results were reported separately for each group. T...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02454140 · results posted 12 September 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT02454140) enrolled 30 people in total across three active groups: 3 participants in Cohort 1, 16 in Cohort 2, and 11 in Cohort 3. Cohorts 4 and 5 had no participants. All 30 people who started the trial completed it. The trial was looking at a type of focused radiation treatment called stereotactic body radiotherapy (SBRT) — a technique that delivers precisely targeted radiation in a small number of sessions — for people with pancreatic cancer. The main thing being measured was the highest dose of radiation (in units calle...
-
NCT03033225 · results posted 30 July 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 13 participants, all of whom received the same treatment — a procedure combining a drug called verteporfin with a light-based technique called photodynamic therapy (PDT), delivered via an ultrasound-guided method into the tumour. The trial was measuring how tumours responded to this approach, specifically by looking at CT scan images taken after the procedure to see whether the tumour showed signs of tissue breakdown (necrosis). The reported data shows that of the 13 people who started the trial, 8 completed it and 5...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT06024174 · results posted 22 July 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT06024174) was studying a combination of two investigational drugs — BMS-986466 and adagrasib — in people with certain cancers. The section of the trial for which results are available (called "Part 1") was specifically looking at how these two drugs interact with each other when taken together, and was tracking safety-related events during that period. Five participants were enrolled in Part 1; none completed the study, and all five left before finishing. The reported data shows that, of the five participants, four experi...
-
NCT05546476 · results posted 29 April 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT05546476) looked at a drug called ponsegromab in people with cancer-related cachexia — a condition where serious illness causes significant weight loss and muscle wasting. The trial was run in two parts (Part A and Part B). In Part A, 187 people were divided into four groups: one group received a placebo (a dummy treatment with no active ingredient), and the other three groups received different doses of ponsegromab (100 mg, 200 mg, or 400 mg). The main thing being measured was how much participants' body weight changed ov...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT04659603 · results posted 25 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04659603) enrolled 50 people across three groups: 6 people with metastatic breast cancer (Cohort A), 28 people with metastatic pancreatic cancer on one treatment regimen (Cohort B), and 16 people with metastatic pancreatic cancer on a different regimen (Cohort C). The trial was measuring how tumours responded to a treatment called tusamitamab ravtansine, as well as tracking how long participants went without their disease getting worse, and recording any medical events that occurred during treatment. The reported data sho...
-
NCT04907851 · results posted 17 March 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04907851) tested a drug called RXC004 across three groups of people with advanced cancers that could not be surgically removed or had spread to other parts of the body. The first group (Module 1) included 6 people with a specific type of advanced pancreatic cancer carrying a genetic change called RNF43 mutation. The second group (Module 2) included 20 people with advanced biliary tract cancer (cancers of the bile ducts and gallbladder) who received RXC004 on its own. The third group (Module 3) included 19 people with advan...
-
NCT03948763 · results posted 28 January 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03948763) enrolled 70 people in total across five groups. Three participants received an experimental treatment called V941 on its own, 15 received V941 combined with another medicine called pembrolizumab as part of an initial dose-testing phase, and a further 52 people were enrolled across three expansion groups focusing on specific cancer types — non-small cell lung cancer (20 people), colorectal cancer (16 people), and pancreatic adenocarcinoma (16 people). The trial was primarily looking at unwanted medical events (cal...
-
NCT00630552 · results posted 17 October 2024
According to the results reported on ClinicalTrials.gov, this trial involved 138 participants in total across five groups. The first, smaller part of the trial (called Phase 1b) tested two different doses of a drug called AMG 655 in 13 people, to look at whether certain serious side effects — known as "dose-limiting toxicities" — occurred. The larger second part (Phase 2) enrolled 125 people across three groups: one receiving AMG 655 (41 people), one receiving a different drug called AMG 479 (42 people), and one receiving a placebo — an inactive substitute (42 people). The main things being me...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02826486 · results posted 28 August 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 80 people with advanced pancreatic cancer across two groups. Thirty-seven participants were in Cohort 1, receiving two drugs — BL-8040 and pembrolizumab (an immunotherapy). Forty-three participants were in Cohort 2, receiving those same two drugs plus chemotherapy. The trial was primarily measuring how many participants' tumours shrank or disappeared based on scans, using a standard imaging measurement system called RECIST 1.1. It also tracked how long participants lived overall, how long they lived without their canc...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03586869 · results posted 27 August 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03586869) tested an experimental treatment called the NANT Pancreatic Cancer Vaccine in people with pancreatic cancer. Three participants were enrolled in the study. None of the three participants completed the trial — all three withdrew or left before it finished, though the reasons for not completing are not detailed in the reported data. The trial was primarily looking at side effects (called adverse events), and also tracking whether tumours shrank and how long participants lived without their disease getting worse. T...
-
NCT04704154 · results posted 23 July 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 175 people across six groups, each with a different type of cancer: head and neck squamous cell cancer who had not previously received immunotherapy (30 people), head and neck squamous cell cancer who had previously received immunotherapy (20 people), oesophageal squamous cell cancer (30 people), pancreatic cancer (20 people), biliary tract cancer (45 people), and brain tumours (glioblastoma/anaplastic astrocytoma, 30 people). The trial was measuring how tumours responded to the study treatment across these different...
-
NCT01231347 · results posted 16 July 2024
According to the results reported on ClinicalTrials.gov, this trial involved 800 people with advanced (metastatic) pancreatic cancer. Participants were divided into three groups: one group received a placebo (an inactive substance) plus the chemotherapy drug gemcitabine (322 people), a second group received a medicine called AMG 479 at a lower dose (12 mg/kg) plus gemcitabine (318 people), and a third group received AMG 479 at a higher dose (20 mg/kg) plus gemcitabine (160 people). The trial was measuring overall survival — that is, how long participants lived from the time they joined the stu...
-
NCT03077685 · results posted 24 June 2024
According to the results reported on ClinicalTrials.gov, this trial tested a drug called NanoPac® (a form of the chemotherapy medicine paclitaxel) injected directly into or around a pancreatic tumour. A total of 54 people took part across three phases. The first phase tested three different concentrations of the drug (6 mg/mL, 10 mg/mL, and 15 mg/mL) in small groups of 3–4 people to assess how the body responded. The second and third phases each used the highest concentration (15 mg/mL) in larger groups of 25 and 19 people respectively. The main thing the trial was set up to measure was how ma...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03387098 · results posted 22 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03387098) enrolled 4 participants, all of whom received a treatment called the NANT Pancreatic Cancer Vaccine. The trial was in its early phase (Phase 1b), and its main goal was to track and record any unwanted health events — called adverse events (unexpected or harmful experiences) and serious adverse events (more severe harmful experiences) — that occurred during treatment. These were rated using a standard medical grading system to describe how severe they were. The reported data shows that the primary outcome measure...
-
NCT06164691 · results posted 21 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT06164691) set out to study whether different types of lighting — blue light, amber light, or standard ambient white light — had any effect on people undergoing chemotherapy and radiation treatment before surgery (known as neoadjuvant chemoradiation). The trial planned to look at several things, including how well the cancer responded to treatment, sleep quality, pain levels, quality of life, physical functioning, and changes in body weight. Only two participants were enrolled, both assigned to the blue light group, and nei...
-
NCT04808362 · results posted 25 April 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT04808362) involved 22 participants, all of whom received the experimental treatment called OMO-103. All 22 participants who started the trial also completed it. The trial was primarily looking at the safety and tolerability of OMO-103 — in other words, it was tracking whether participants experienced certain types of side effects or adverse reactions. It also measured how long the treatment took to be processed and cleared by the body. The reported data shows that, out of the 22 participants: 1 person experienced what is...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 127 reported results for Pancreatic Cancer
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, pancreatic cancer currently attracts a very large amount of public research investment from the United States government. The direction of that funding has remained broadly steady year on year, which suggests the field is receiving consistent, sustained attention from the research community rather than experiencing sharp rises or falls in interest. For patients, this...
See the full Pancreatic Cancer page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.